Honoring Sharon Peterson: A Legacy of Leadership and STEM Education

In recognition of her extraordinary contributions, Sharon has been inducted into the Montana Bioscience Hall of Fame, a fitting tribute to her enduring impact on our bioscience community. And to further honor her legacy, we are proud to announce the creation of the Sharon Peterson STEM Scholarship.

C2M Beta Cohort Applications Open

2M Beta is a 12-week program delivering the foundational and modern skills required to transform influential ideas into thriving businesses. With access to more professional expertise, more state-of-the-art technology and more community resources, C2M Beta was founded with the mission to connect local entrepreneurs to more!

SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems

SPI Pharma, Inc. a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, announce an agreement in principle to create a strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development. This collaboration leverages Inimmune’s world-class expertise in adjuvant formulation and immunotherapeutics and SPI Pharma’s extensive manufacturing and global commercial capabilities.

Montana Biotech Companies to Watch 2024

Since 2017, the Montana High Tech Business Alliance has annually showcased top tech companies in Montana. This year, in partnership with the Montana Bioscience Cluster Initiative, we present the 2024 Montana Biotech Companies to Watch. These companies are leading the charge in biotech innovation, from improving healthcare for underserved populations to using AI for remote health monitoring and revolutionizing drug discovery with advanced tools.

NIAID Targets Transport System as Lyme Disease Treatment

NIAID scientists and colleagues are investigating a potential treatment strategy against Lyme disease that would directly suppress Borrelia burgdorferi, the bacterium that causes the disease. If successful, their idea could reduce or end aggressive broad-spectrum antibiotic treatments that can be drawn-out and destroy the body’s helpful bacteria.